You are here

Dose Confusion Can Occur With Avycaz, FDA Warns

Medication errors are possible with ceftazidime/avibactam combo

Health care professionals should be alert to the risk for dosing errors with the intravenous antibacterial drug ceftazidime/avibactam (Avycaz, Forest Pharmaceuticals Inc.) due to confusion about the drug strength displayed on the vial and carton labels, the FDA says.

Avycaz was initially approved with the vial and carton labels displaying the individual strengths of the two active ingredients (e.g., 2 g/0.5 g); however, the product is dosed based on the sum of the active ingredients (e.g., 2.5 g). To prevent medication errors, the agency revised the labels to indicate that each vial contains Avycaz 2.5 g, equivalent to ceftazidime 2 g and avibactam 0.5 g.

Since Avycaz’s approval in February 2015, the FDA has received reports of three medication error cases related to confusion about how the strength was displayed on the Avycaz vial and carton labels. In two cases, the errors occurred during preparation of the dose in the pharmacy. The third case involved concern about the potential for confusion because the strength displayed for Avycaz differs from how the strength is displayed for other beta-lactam/beta-lactamase drugs.

At least one patient received a higher-than-intended dose of Avycaz. No adverse events were reported.

Avycaz is approved for intravenous administration to treat complicated infections in the urinary tract, or in combination with the antibacterial drug metronidazole to treat complicated infections in the abdomen in patients with limited or no alternative treatment options.

Health care professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.

Source: FDA, September 22, 2015.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation